Description

Dota-D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-Ol (Disulfide Bridge: 2-7) is a synthetic, cyclic octapeptide analog of somatostatin, engineered with a disulfide bond between cysteine residues at positions 2 and 7 for enhanced structural stability and biological activity. This compound is a critical intermediate and reference standard in the development of targeted radiopharmaceuticals for diagnostic imaging and therapeutic applications. It is essential for researchers and manufacturers in the fields of nuclear medicine, oncology research, and peptide-based drug discovery who require high-purity, well-characterized building blocks for advanced theranostic agents.

Application

• Radiopharmaceutical Precursor: Primary building block for synthesizing peptide receptor radionuclide therapy (PRRT) agents, such as those labeled with Lutetium-177 or Yttrium-90, targeting somatostatin receptor-positive tumors.
• Diagnostic Imaging Agent: Chelation site for radionuclides like Gallium-68 for use in Positron Emission Tomography (PET) imaging, enabling precise tumor localization and staging.
• Oncology Research: A key reference standard and tool compound for studying somatostatin receptor (SSTR) binding, internalization, and signaling pathways in cancer cell lines and models.
• Theranostic Development: Serves as the core peptide structure in theranostic pairs, where the same targeting vector is used for both diagnosis and therapy.
• Peptide Chemistry & Conjugation: Used in advanced research on peptide-drug conjugates, stability studies, and the development of novel chelator-peptide constructs.
• Quality Control & Validation: Acts as a critical system suitability standard and impurity marker in the HPLC and MS analysis of finished radiopharmaceutical drug products.

Basic Information

Product Name	Dota-D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-Ol (Disulfide Bridge: 2-7)
CAS No.	204318-14-9
Molecular Formula	C58H78N14O16S2
Molecular Weight	1291.46 g/mol
Synonyms	DOTA-(D)Phe-Cys-Tyr-(D)Trp-Lys-Thr-Cys-Thr-ol (cyclic 2-7 disulfide); DOTA-TATE precursor; DOTA-[Tyr3]-Octreotate analog; DOTA-conjugated somatostatin analog; DOTA-SSA; (2,2',2'',2'''-(1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetrayl)tetraacetic acid)-D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-ol (2-7 disulfide); DOTA-Octreotate derivative; DOTA-LM3 intermediate
EINECS	Contact for details

Quality Control

Our Dota-D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-Ol (Disulfide Bridge: 2-7) is manufactured under strict quality management systems. Each batch undergoes rigorous analytical testing, including HPLC for purity and identity confirmation, mass spectrometry (MS) for structural verification, and amino acid analysis (AAA). We provide comprehensive Certificates of Analysis (COA) with detailed chromatographic data, ensuring traceability and compliance with research and cGMP-grade material expectations for critical pharmaceutical development.

Storage

Preserve in a tightly closed container, protected from light. Store at -20°C or below in a dedicated freezer. This product is hygroscopic (moisture-sensitive); allow the sealed vial to equilibrate to room temperature before opening to prevent condensation. For long-term storage, consider under an inert atmosphere.

Specification

Item	Specification
Appearance	White to off-white lyophilized powder
Identification (HPLC)	Retention time corresponds to reference standard
Identification (MS)	Mass spectrum confirms molecular ion
Purity (HPLC)	≥ 95.0%
Related Substances (HPLC)	Total impurities ≤ 5.0%
Water Content (KF)	≤ 5.0%
Peptide Content (AAA)	≥ 80.0%
Solvent Residues (GC)	Meets ICH guidelines

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.